Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

@article{Ledermann2011PhaseIR,
  title={Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).},
  author={Jonathan A Ledermann and Philipp Harter and Charlie Gourley and Michael Friedlander and Ignace Vergote and Gordon J.S. Rustin and Charles J C Scott and Werner Meier and Ronnie Shapira-Frommer and Tamar Safra and Daniela Elena Matei and Euan Macpherson and Cathy A Watkins and James Carmichael and Ursula A. Matulonis},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={5003}
}
5003 Background: Olaparib (AZD2281) is an oral PARP inhibitor that has shown antitumor activity in patients (pts) with high-grade serous ovarian cancer (SOC) with and without BRCA1 or BRCA2 mutations. This randomized, double-blind, multicenter, placebo-controlled Phase II study evaluated maintenance treatment with olaparib in pts with high-grade PSR SOC (clinicaltrials.gov; NCT00753545 ). METHODS Pts with PSR SOC who had received ≥2 previous platinum regimens and were in a maintained partial… CONTINUE READING